[Federal Register: May 14, 2008 (Volume 73, Number 94)]
[Rules and Regulations]
[Page 27748-27756]
[DOCID:fr14my08-13]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA-HQ-OPP-2005-0097; FRL-8364-6]

Tebuconazole; Pesticide Tolerances

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This regulation establishes tolerances for residues of
tebuconazole in or on wheat, barley, and tree nuts. Bayer CropScience
LP requested these tolerances under the Federal Food, Drug, and
Cosmetic Act (FFDCA).

DATES: This regulation is effective May 14, 2008. Objections and
requests for hearings must be received on or before July 14, 2008, and
must be filed in accordance with the instructions provided in 40 CFR
part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).

ADDRESSES: EPA has established a docket for this action under docket
identification (ID) number EPA-HQ-OPP-2005-0097. To access the
electronic docket, go to http://www.regulations.gov, select ``Advanced
Search,'' then ``Docket Search.'' Insert the docket ID number where
indicated and select the ``Submit'' button. Follow the instructions on
the regulations.gov website to view the docket index or access
available documents. All documents in the docket are listed in the
docket index available in regulations.gov. Although listed in the
index, some information is not publicly available, e.g., Confidential
Business Information (CBI) or other information whose disclosure is
restricted by statute. Certain other material, such as copyrighted
material, is not placed on the Internet and will be publicly available
only in hard copy form. Publicly available docket materials are
available in the electronic docket at http://www.regulations.gov, or,
if only available in hard copy, at the OPP Regulatory Public Docket in
Rm. S-4400, One Potomac Yard (South Bldg.), 2777 S. Crystal Dr.,
Arlington, VA. The Docket Facility is open from 8:30 a.m. to 4 p.m.,
Monday through Friday, excluding legal holidays. The Docket Facility
telephone number is<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Tracy Keigwin, Registration Division
(7505P), Office of Pesticide Programs, Environmental Protection Agency,
1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone
number:<PHONE_NUMBER>; e-mail address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

    You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
Potentially affected entities may include, but are not limited to those
engaged in the following activities:
     Crop production (NAICS code 111).
     Animal production (NAICS code 112).
     Food manufacturing (NAICS code 311).
     Pesticide manufacturing (NAICS code 32532).
    This listing is not intended to be exhaustive, but rather to
provide a guide for readers regarding entities likely to be affected by
this action. Other types of entities not listed in this unit could also
be affected. The North American Industrial Classification System
(NAICS) codes have been provided to assist you and others in
determining whether this action might apply to certain entities. If you
have any questions regarding the applicability of this action to a
particular entity, consult the person listed under FOR FURTHER
INFORMATION CONTACT.

B. How Can I Access Electronic Copies of this Document?

    In addition to accessing an electronic copy of this Federal
Register document through the electronic docket at http://
www.regulations.gov, you may access this Federal Register document
electronically through the EPA Internet under the ``Federal Register''
listings at http://www.epa.gov/fedrgstr. You may also access a
frequently updated electronic version of EPA's tolerance regulations at
40 CFR part 180 through the Government Printing Office's pilot e-CFR
site at http://www.gpoaccess.gov/ecfr.

C. Can I File an Objection or Hearing Request?

    Under section 408(g) of FFDCA, any person may file an objection to
any

aspect of this regulation and may also request a hearing on those
objections. You must file your objection or request a hearing on this
regulation in accordance with the instructions provided in 40 CFR part
178. To ensure proper receipt by EPA, you must identify docket ID
number EPA-HQ-OPP-2005-0097 in the subject line on the first page of
your submission. All requests must be in writing, and must be mailed or
delivered to the Hearing Clerk as required by 40 CFR part 178 on or
before July 14, 2008.
    In addition to filing an objection or hearing request with the
Hearing Clerk as described in 40 CFR part 178, please submit a copy of
the filing that does not contain any CBI for inclusion in the public
docket that is described in ADDRESSES. Information not marked
confidential pursuant to 40 CFR part 2 may be disclosed publicly by EPA
without prior notice. Submit this copy, identified by docket ID number
EPA-HQ-OPP-2005-0097, by one of the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the on-line instructions for submitting comments.
     Mail: Office of Pesticide Programs (OPP) Regulatory Public
Docket (7502P), Environmental Protection Agency, 1200 Pennsylvania
Ave., NW., Washington, DC 20460-0001.
     Delivery: OPP Regulatory Public Docket (7502P),
Environmental Protection Agency, Rm. S-4400, One Potomac Yard (South
Bldg.), 2777 S. Crystal Dr., Arlington, VA. Deliveries are only
accepted during the Docket's normal hours of operation (8:30 a.m. to 4
p.m., Monday through Friday, excluding legal holidays). Special
arrangements should be made for deliveries of boxed information. The
Docket Facility telephone number is<PHONE_NUMBER>.

II. Petition for Tolerance

    In the Federal Register of May 18, 2005 (70 FR 28257) (FRL-7708-5),
EPA issued a notice pursuant to section 408(d)(3) of FFDCA, 21 U.S.C.
346a(d)(3), announcing the filing of a pesticide petition (PP 7F4895)
by Bayer CropScience LP, P.O. Box 12014, 2 T.W. Alexander Drive,
Research Triangle Park, NC 27709. The petition requested that 40 CFR
180.474 be amended by establishing tolerances for residues of the
fungicide tebuconazole, alpha-[2-(4-Chlorophenyl)ethyl]-alpha-(1,1-
dimethylethyl)-1H-1,2,4-triazole-1-ethanol, in or on food commodities
nut, tree, group 14 at 0.05 ppm; almond, hulls at 5.0 ppm; pistachio at
0.05 ppm; barley, hay at 6.0 ppm; barley, straw at 1.4 ppm; wheat,
forage at 3.0 ppm; wheat, hay at 6.0 ppm; wheat, straw at 1.4 ppm. That
notice referenced a summary of the petition prepared by Bayer
CropScience LP, the registrant, which is available to the public in the
docket, http://www.regulations.gov. Comments were received on the
notice of filing. EPA's response to these comments is discussed in Unit
IV.C.
    Based upon review of the data supporting the petition, EPA has
modified the proposed tolerances as follows: Almond, hulls at 6.0 ppm;
barley, grain at 0.15 ppm, barley, hay at 7.0 ppm; barley, straw at 3.5
ppm; wheat grain at 0.05 ppm, wheat, hay at 7.0 ppm; wheat, straw at
1.5 ppm; and a separate pistachio tolerance is not needed. The reason
for these changes is explained in Unit IV.D.

III. Aggregate Risk Assessment and Determination of Safety

    Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a
tolerance (the legal limit for a pesticide chemical residue in or on a
food) only if EPA determines that the tolerance is ``safe.'' Section
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a
reasonable certainty that no harm will result from aggregate exposure
to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable
information.'' This includes exposure through drinking water and in
residential settings, but does not include occupational exposure.
Section 408(b)(2)(C) of FFDCA requires EPA to give special
consideration to exposure of infants and children to the pesticide
chemical residue in establishing a tolerance and to ``ensure that there
is a reasonable certainty that no harm will result to infants and
children from aggregate exposure to the pesticide chemical
residue....''
    Consistent with section 408(b)(2)(D) of FFDCA, and the factors
specified in section 408(b)(2)(D) of FFDCA, EPA has reviewed the
available scientific data and other relevant information in support of
this action. EPA has sufficient data to assess the hazards of and to
make a determination on aggregate exposure for the petitioned-for
tolerances for residues of tebuconazole. EPA's assessment of exposures
and risks associated with establishing tolerances follows.

A. Toxicological Profile

    EPA has evaluated the available toxicity data and considered its
validity, completeness, and reliability as well as the relationship of
the results of the studies to human risk. EPA has also considered
available information concerning the variability of the sensitivities
of major identifiable subgroups of consumers, including infants and
children.
    Tebuconazole has low acute toxicity by the oral or dermal route of
exposure, and moderate toxicity by the inhalation route. It is not a
dermal sensitizer or a dermal irritant; however, it is slightly to
mildly irritating to the eye. The main target organs are the liver, the
adrenals, the hematopoetic system and the nervous system. Effects on
these target organs were seen in both rodent and non-rodent species. In
addition, ocular lesions are seen in dogs (including lenticular
degeneration and increased cataract formation) following subchronic or
chronic exposure.
    Oral administration of tebuconazole caused developmental toxicity
in all species evaluated (rat, rabbit, and mouse), with the most
prominent effects seen in the developing nervous system. In the
available toxicity studies on tebuconazole, there was no
toxicologically significant evidence of endocrine disruptor effects.
Tebuconazole was classified as a Group C - possible human carcinogen,
based on an increase in the incidence of hepatocellular adenomas,
carcinomas and combined adenomas/carcinomas in male and female mice.
Submitted mutagenicity studies did not demonstrate any evidence of
mutagenic potential for tebuconazole. Tebuconazole shares common
metabolites with other triazole-derivative chemicals, including free
triazole (1,2,4-triazole) and triazole-conjugated plant metabolites
(such as triazole alanine). These common metabolites have been the
subject of separate risk assessments.
    Specific information on the studies received and the nature of the
adverse effects caused by tebuconazole as well as the no-observed-
adverse-effect-level (NOAEL) and the lowest-observed-adverse-effect-
level (LOAEL) from the toxicity studies can be found at http://
www.regulations.gov in document entitled Tebuconazole: Human Health
Risk Assessment to support tolerances in/on Asparagus, Barley, Beans,
Beets, Brassica leafy greens, Bulb Vegetables, Coffee (import),
Commercial Ornamentals, Corn, Cotton, Cucurbits, Hops, Lychee, Mango,
Okra, Pome fruit, Soybean, Stone fruit, Sunflower, Tree Nut Crop Group,
Turf, Turnips and Wheat, pages 79-107 in docket ID number EPA-HQ-OPP-
2005[dash]0097.

B. Toxicological Endpoints

    For hazards that have a threshold below which there is no
appreciable risk, a toxicological point of departure

(POD) is identified as the basis for derivation of reference values for
risk assessment. The POD may be defined as the highest dose at which no
adverse effects are observed (the NOAEL) in the toxicology study
identified as appropriate for use in risk assessment. However, if a
NOAEL cannot be determined, the lowest dose at which adverse effects of
concern are identified (the LOAEL) or a Benchmark Dose (BMD) approach
is sometimes used for risk assessment. Uncertainty/safety factors (UFs)
are used in conjunction with the POD to take into account uncertainties
inherent in the extrapolation from laboratory animal data to humans and
in the variations in sensitivity among members of the human population
as well as other unknowns. Safety is assessed for acute and chronic
dietary risks by comparing aggregate food and water exposure to the
pesticide to the acute population adjusted dose (aPAD) and chronic
population adjusted dose (cPAD). The aPAD and cPAD are calculated by
dividing the POD by all applicable UFs. Aggregate short-, intermediate-
, and chronic-term risks are evaluated by comparing food, water, and
residential exposure to the POD to ensure that the margin of exposure
(MOE) called for by the product of all applicable UFs is not exceeded.
This latter value is referred to as the Level of Concern (LOC).
    For non-threshold risks, the Agency assumes that any amount of
exposure will lead to some degree of risk. Thus, the Agency estimates
risk in terms of the probability of an occurrence of the adverse effect
greater than that expected in a lifetime. For more information on the
general principles EPA uses in risk characterization and a complete
description of the risk assessment process, see http://www.epa.gov/
pesticides/factsheets/riskassess.htm.
    A summary of the toxicological endpoints for tebuconazole used for
human risk assessment is shown in Table 1 of this unit.

      Table 1. -- Summary of Toxicological Doses and Endpoints for Tebuconazole for Use in Dietary and Non-
                                   Occupational Human Health Risk Assessments
----------------------------------------------------------------------------------------------------------------
                                                                          RfD, PAD, Level of       Study and
        Exposure/Scenario         Point of Departure   Uncertainty/FQPA    Concern for Risk      Toxicological
                                                        Safety Factors        Assessment            Effects
----------------------------------------------------------------------------------------------------------------
Acute Dietary (General            LOAEL = 8.8 mg/kg/  UFA= 10x            Acute RfD = 0.029   Developmental
 Population, including Infants     day                UFH=10x...........   mg/kg/day           Neurotoxicity
 and Children)                    UF = 300..........  FQPA(UFL)= 3x.....  aPAD = 0.029 mg/kg/  Study - Rat.
                                                                           day.               LOAEL = 8.8 mg/kg/
                                                                                day based on
                                                                                decreases in body
                                                                                weights, absolute
                                                                                brain weights,
                                                                                brain
                                                                                measurements and
                                                                                motor activity in
                                                                                offspring.
----------------------------------------------------------------------------------------------------------------
Chronic Dietary (All              LOAEL = 8.8 mg/kg/  UFA= 10x            Chronic RfD =       Developmental
 Populations)                      day                UFH=10x...........   0.029mg/kg/day      Neurotoxicity
                                  UF = 300..........  FQPA(UFL)= 3x.....  cPAD =0.029 mg/kg/   Study - Rat.
                                                                           day.               LOAEL = 8.8 mg/kg/
                                                                                day based on
                                                                                decreases in body
                                                                                weights, absolute
                                                                                brain weights,
                                                                                brain
                                                                                measurements and
                                                                                motor activity in
                                                                                offspring.
----------------------------------------------------------------------------------------------------------------
Incidental Oral Short-/           LOAEL = 8.8 mg/kg/  UFA= 10x            Residential LOC     Developmental
 Intermediate-Term (1-30 days/1-   day                UFH=10x...........   for MOE = 300       Neurotoxicity
 6 months)                        UF = 300..........  FQPA(UFL)= 3x.....                       Study - Rat.
                                                                                LOAEL = 8.8 mg/kg/
                                                                                day based on
                                                                                decreases in body
                                                                                weights, absolute
                                                                                brain weights,
                                                                                brain
                                                                                measurements and
                                                                                motor activity in
                                                                                offspring.
----------------------------------------------------------------------------------------------------------------
Dermal Short-/Intermediate-Term   LOAEL = 8.8 mg/kg/  UFA= 10x            Residential LOC     Developmental
 (1-30 days/1-6 months)            day                UFH=10x...........   for MOE = 300       Neurotoxicity
                                  UF = 300..........  FQPA (UFL)= 3x....                       Study - Rat.
                                                      DAF = 23.1%.......                      LOAEL = 8.8 mg/kg/
                                                                                day based on
                                                                                decreases in body
                                                                                weights, absolute
                                                                                brain weights,
                                                                                brain
                                                                                measurements and
                                                                                motor activity in
                                                                                offspring.
----------------------------------------------------------------------------------------------------------------
Inhalation Short-/Intermediate-   LOAEL = 8.8 mg/kg/  UFA= 10x            Residential LOC     Developmental
 Term (1-30 days/1-6 months)       day                UFH=10x...........   for MOE = 300       Neurotoxicity
                                  UF = 300..........  FQPA (UFL)= 3x....                       Study - Rat.
                                                      Inhalation and                          LOAEL = 8.8 mg/kg/
                                                       oral toxicity are                       day based on
                                                       assumed to be                           decreases in body
                                                       equivalent.                             weights, absolute
                                                                                brain weights,
                                                                                brain
                                                                                measurements and
                                                                                motor activity in
                                                                                offspring.
----------------------------------------------------------------------------------------------------------------

Cancer (oral, dermal,                Classification: Group C- possible human carcinogen based on statistically
 inhalation)                        significant increase in the incidence of hepatocellular adenoma, carcinoma,
                                    and combined adenoma/carcinomas in both sexes of NMRI mice. Considering that
                                     there was no evidence of carcinogenicity in rats, there was no evidence of
                                       genotoxicity for tebuconazole, and tumors were only seen at a high and
                                    excessively toxic dose in mice, EPA concluded that the chronic RfD would be
                                     protective of any potential carcinogenic effect. The chronic RfD value is
                                     0.029 mg/kg/day which is approximately 9600 fold lower than the dose that
                                                     would induce liver tumors (279 mg/kg/day).
----------------------------------------------------------------------------------------------------------------
Point of Departure (POD) = A data point or an estimated point that is derived from observed dose-response data
  and used to mark the beginning of extrapolation to determine risk associated with lower environmentally
  relevant human exposures. NOAEL = no observed adverse effect level. LOAEL = lowest observed adverse effect
  level. UF = uncertainty factor. UFA = extrapolation from animal to human (interspecies). UFH = potential
  variation in sensitivity among members of the human population (intraspecies). UFL = use of a LOAEL to
  extrapolate a NOAEL. FQPA SF = FQPA Safety Factor. PAD = population adjusted dose (a = acute, c = chronic).
  RfD = reference dose. MOE = margin of exposure. LOC = level of concern. N/A = not applicable. DAF = dermal
  absorption factor.

C. Exposure Assessment

    1. Dietary exposure from food and feed uses. In evaluating dietary
exposure to tebuconazole, EPA considered exposure under the petitioned-
for tolerances, including other pending petitions, as well as all
existing tebuconazole tolerances in (40 CFR 180.474). EPA assessed
dietary exposures from tebuconazole in food as follows:
    i. Acute exposure. Quantitative acute dietary exposure and risk
assessments are performed for a food-use pesticide, if a toxicological
study has indicated the possibility of an effect of concern occurring
as a result of a 1-day or single exposure.
    In estimating acute dietary exposure, EPA used food consumption
information from the United States Department of Agriculture (USDA)
1994-1996 and 1998 Nationwide Continuing Surveys of Food Intake by
Individuals (CSFII). As to residue levels in food, anticipated residues
for bananas, grapes, raisins, nectarines, peaches and peanut butter
were derived using the latest USDA Pesticide Data Program (PDP)
monitoring data from 2002- 2006. Anticipated residues for all other
registered and proposed food commodities were based on field trial
data. For uses associated with PP 7F4895, 100% Crop treated was
assumed. DEEM (ver. 7.81) default processing factors were assumed for
processed commodities associated with petition 7F4895. For several
other uses EPA used percent crop treated (PCT) data as specified in
Unit III.C.1.iv.
    ii. Chronic exposure. In conducting the chronic dietary exposure
assessment EPA used the same assumptions as stated in Unit III. C.1.i.
for acute exposure.
    iii. Cancer. As explained in Unit III.B., the chronic risk
assessment is considered to be protective of any cancer effects;
therefore, a separate quantitative cancer dietary risk assessment was
not conducted.
    iv. Anticipated residue and PCT information. Section 408(b)(2)(E)
of FFDCA authorizes EPA to use available data and information on the
anticipated residue levels of pesticide residues in food and the actual
levels of pesticide residues that have been measured in food. If EPA
relies on such information, EPA must require pursuant to FFDCA section
408(f)(1) that data be provided 5 years after the tolerance is
established, modified, or left in effect, demonstrating that the levels
in food are not above the levels anticipated. For the present action,
EPA will issue such data call-ins as are required by FFDCA section
408(b)(2)(E) and authorized under FFDCA section 408(f)(1). Data will be
required to be submitted no later than 5 years from the date of
issuance of these tolerances.
    Section 408(b)(2)(F) of FFDCA states that the Agency may use data
on the actual percent of food treated for assessing chronic dietary
risk only if:
     Condition a: The data used are reliable and provide a valid basis
to show what percentage of the food derived from such crop is likely to
contain the pesticide residue.
    Condition b: The exposure estimate does not underestimate exposure
for any significant subpopulation group.
    Condition c: Data are available on pesticide use and food
consumption in a particular area, the exposure estimate does not
understate exposure for the population in such area.
In addition, the Agency must provide for periodic evaluation of any
estimates used. To provide for the periodic evaluation of the estimate
of PCT as required by FFDCA section 408(b)(2)(F), EPA may require
registrants to submit data on PCT.
    The Agency used PCT information for tebuconazole on grapes, grape,
raisin, nectarine, oats, peach, and peanuts. The PCT for each crop is
as follows: Grapes: 25%; grape, raisin: 25%; nectarine 25%; oats 2.5%;
peach: 20%; and peanuts 45%.
    In most cases, EPA uses available data from United States
Department of Agriculture/National Agricultural Statistics Service
(USDA/NASS), proprietary market surveys, and the National Pesticide Use
Database for the chemical/crop combination for the most recent 6 years.
EPA uses an average PCT for chronic dietary risk analysis. The average
PCT figure for each existing use is derived by combining available
public and private market survey data for that use, averaging across
all observations, and rounding to the nearest 5%, except for those
situations in which the average PCT is less than one. In those cases,
1% is used as the average PCT and 2.5% is used as the maximum PCT. EPA
uses a maximum PCT for acute dietary risk analysis. The maximum PCT
figure is the highest observed maximum value reported within the recent
6 years of available public and private market survey data for the
existing use and rounded up to the nearest multiple of 5%.
    The Agency used projected percent crop treated (PPCT) information
for tebuconazole on cherries (pre-harvest) and cherries (post-harvest).
The PCT for each crop is as follows: Cherries, pre-harvest: acute
assessment 42%, chronic assessment 37%; Cherries, post-harvest: acute
assessment 100%, chronic assessment 66%. EPA estimates PPCT for a new
pesticide use by assuming that its actual PCT during the initial five
years of use on a specific use site will not exceed the recent PCT of
the market leader (i.e., the one with the greatest PCT) on that site.
An average market leader PCT, based on three recent surveys of
pesticide usage, if available, is used for chronic risk assessment,

while the maximum PCT from the same three recent surveys, if available,
is used for acute risk assessment. The average and maximum market
leader PCTs may each be based on one or two surveys if three are not
available. Comparisons are only made among pesticides of the same
pesticide types (i.e., the leading fungicide on the use site is
selected for comparison with the new fungicide). The market leader PCTs
used to determine the average and the maximum may be each for the same
pesticide or for different pesticides since the same or different
pesticides may dominate for each year. Typically, EPA uses USDA/NASS as
the source for raw PCT data because it is publicly available. When a
specific use site is not surveyed by USDA/NASS, EPA uses other sources
including proprietary data.
    An estimated PPCT, based on the average PCT of the market leaders,
is appropriate for use in chronic dietary risk assessment, and an
estimated PPCT, based on the maximum PCT of the market leaders, is
appropriate for use in acute dietary risk assessment. This method of
estimating PPCTs for a new use of a registered pesticide or a new
pesticide produces high-end estimates that are unlikely, in most cases,
to be exceeded during the initial five years of actual use. Predominant
factors that bear on whether the PPCTs could be exceeded may include
PCTs of similar chemistries, pests controlled by alternatives, pest
prevalence in the market and other factors. All relevant information
currently available for predominant factors have been considered for
tebuconazole on cherries, resulting in adjustments to the initial
estimates for three crops to account for lack of confidence in
projections based on less than three observations, old data and/or data
based on expert opinion.
    The Agency believes that the three conditions discussed in Unit
III.C.1.iv. have been met. With respect to Condition a, PCT estimates
are derived from Federal and private market survey data, which are
reliable and have a valid basis, or conservative estimates based on
information from agricultural experts. The Agency is reasonably certain
that the percentage of the food treated is not likely to be an
underestimation. As to Conditions b and c, regional consumption
information and consumption information for significant subpopulations
is taken into account through EPA's computer-based model for evaluating
the exposure of significant subpopulations including several regional
groups. Use of this consumption information in EPA's risk assessment
process ensures that EPA's exposure estimate does not understate
exposure for any significant subpopulation group and allows the Agency
to be reasonably certain that no regional population is exposed to
residue levels higher than those estimated by the Agency. Other than
the data available through national food consumption surveys, EPA does
not have available reliable information on the regional consumption of
food to which tebuconazole may be applied in a particular area.
    2. Dietary exposure from drinking water. The Agency used screening
level water exposure models in the dietary exposure analysis and risk
assessment for tebuconazole in drinking water. These simulation models
take into account data on the physical, chemical, and fate/transport
characteristics of tebuconazole. Further information regarding EPA
drinking water models used in pesticide exposure assessment can be
found at http://www.epa.gov/oppefed1/models/water/index.htm.
    Based on the Pesticide Root Zone Model /Exposure Analysis Modeling
System (PRZM/EXAMS) and Screening Concentration in Ground Water (SCI-
GROW) models, the estimated drinking water concentrations (EDWCs) of
tebuconazole for acute exposures are estimated to be 78.5 parts per
billion (ppb) for surface water and 1.56 ppb for ground water. The
EDWCs for chronic, non-cancer are estimated to be 44.9 ppb for surface
water and 1.56 ppb for ground water. The EDWCs for chronic, cancer
exposures are estimated to be 32.3 ppb for surface water and 1.56 ppb
for ground water.
    Modeled estimates of drinking water concentrations were directly
entered into the dietary exposure model. For the acute dietary risk
assessment, the water concentration value of 78.5 ppb was used to
assess the contribution to drinking water. For the chronic dietary risk
assessment (which is protective of any possible cancer effects), the
water concentration value of 44.9 ppb was used to assess the
contribution to drinking water.
    3. From non-dietary exposure. The term ``residential exposure'' is
used in this document to refer to non-occupational, non-dietary
exposure (e.g., for lawn and garden pest control, indoor pest control,
termiticides, and flea and tick control on pets).
    Tebuconazole is currently registered for uses that could result in
residential exposures. Short-term dermal and inhalation exposures are
possible for residential adult handlers mixing, loading, and applying
tebuconazole products outdoors to ornamental plants. Short- and
intermediate-term dermal postapplication exposures to adults during
golfing and children playing on treated wood structures are also
possible. Children may also be exposed via the incidental oral route
when playing on treated wood structures. Long-term exposure is not
expected. As a result, risk assessments have been completed for
residential handler scenarios as well as residential postapplication
scenarios.
    4. Cumulative effects from substances with a common mechanism of
toxicity. Section 408(b)(2)(D)(v) of FFDCA requires that, when
considering whether to establish, modify, or revoke a tolerance, the
Agency consider ``available information'' concerning the cumulative
effects of a particular pesticide's residues and ``other substances
that have a common mechanism of toxicity.''
    Tebuconazole is a member of the triazole-containing class of
pesticides. Although conazoles act similarly in plants (fungi) by
inhibiting ergosterol biosynthesis, there is not necessarily a
relationship between their pesticidal activity and their mechanism of
toxicity in mammals. Structural similarities do not constitute a common
mechanism of toxicity. Evidence is needed to establish that the
chemicals operate by the same, or essentially the same, sequence of
major biochemical events. In conazoles, however, a variable pattern of
toxicological responses is found. Some are hepatotoxic and
hepatocarcinogenic in mice. Some induce thyroid tumors in rats. Some
induce developmental, reproductive, and neurological effects in
rodents. Furthermore, the conazoles produce a diverse range of
biochemical events including altered cholesterol levels, stress
responses, and altered DNA methylation. It is not clearly understood
whether these biochemical events are directly connected to their
toxicological outcomes. Thus, there is currently no evidence to
indicate that conazoles share common mechanisms of toxicity and EPA is
not following a cumulative risk approach based on a common mechanism of
toxicity for the conazoles. For information regarding EPA's procedures
for cumulating effects from substances found to have a common mechanism
of toxicity, see EPA's website at http://www.epa.gov/pesticides/
cumulative.
    Triazole-derived pesticides can form the common metabolite 1,2,4-
triazole and two triazole conjugates (triazole alanine and triazole
acetic acid). To support existing tolerances and to establish new
tolerances for triazole-derivative pesticides, including tebuconazole,
EPA conducted a human health risk assessment for exposure to

1,2,4-triazole, triazole alanine, and triazole acetic acid resulting
from the use of all current and pending uses of any triazole-derived
fungicide as of September 1, 2005. The risk assessment is a highly
conservative, screening-level evaluation in terms of hazards associated
with common metabolites (e.g., use of a maximum combination of
uncertainty factors) and potential dietary and non-dietary exposures
(i.e., high end estimates of both dietary and non-dietary exposures).
In addition, the Agency retained the additional 10X FQPA safety factor
for the protection of infants and children. The assessment includes
evaluations of risks for various subgroups, including those comprised
of infants and children. The Agency's September 1, 2005 risk assessment
can be found in the propiconazole reregistration docket at http://
www.regulations.gov (Docket ID EPA-HQ-OPP-2005-0497). An addendum to
the risk assessment, Dietary Exposure Assessments for the Common
Triazole Metabolites 1,2,4-triazole, Triazolylalanine, Triazolylacetic
Acid and Triazolylypyruvic Acid; Updated to Include New Uses of
Fenbuconazole, Ipconazole, Metconazole, Tebuconazole, and Uniconazole
can be found at http://www.regulations.gov in docket ID EPA-HQ-OPP-
2005-0097.

D. Safety Factor for Infants and Children

    1. In general. Section 408(b)(2)(c) of FFDCA provides that EPA
shall apply an additional tenfold (10X) margin of safety for infants
and children in the case of threshold effects to account for prenatal
and postnatal toxicity and the completeness of the database on toxicity
and exposure unless EPA determines based on reliable data that a
different margin of safety will be safe for infants and children. This
additional margin of safety is commonly referred to as the FQPA safety
factor (SF). In applying this provision, EPA either retains the default
value of 10X, or uses a different additional safety factor when
reliable data available to EPA support the choice of a different
factor.
    2. Prenatal and postnatal sensitivity. The toxicity database for
tebuconazole is complete, and includes prenatal developmental toxicity
studies in three species (mouse, rat, and rabbit), a reproductive
toxicity study in rats, acute and subchronic neurotoxicity studies in
rats, and a developmental neurotoxicity study in rats. The data from
prenatal developmental toxicity studies in mice and a developmental
neurotoxicity (DNT) study in rats indicated an increased quantitative
and qualitative susceptibility following in utero exposure to
tebuconazole. The NOAELs/LOAELs for developmental toxicity in the mouse
study were found at dose levels less than those that induces maternal
toxicity or in the presence of slight maternal toxicity. In the DNT
study, the LOAEL at which developmental toxicity was seen was below the
NOAEL for maternal animals. No NOAEL was identified for the offspring
in this study. There was no indication of increased quantitative
susceptibility in the rat and rabbit developmental toxicity studies,
the NOAELs for developmental toxicity were comparable to or higher than
the NOAELs for maternal toxicity. In all three species, however, there
was indication of increased qualitative susceptibility. For most
studies, minimal maternal toxicity was seen at the LOAEL (consisting of
increases in hematological findings in mice, increased liver weights in
rabbits and rats, and decreased body weight gain/food consumption in
rats) and did not increase substantially in severity at higher doses;
however, there was more concern for the developmental effects at each
LOAEL which included increases in runts, increased fetal loss, and
malformations in mice, increased skeletal variations in rats, and
increased fetal loss and frank malformations in rabbits. Additionally,
more severe developmental effects (including frank malformations) were
seen at higher doses in mice, rats and rabbits. In the developmental
neurotoxicity study, maternal toxicity was seen only at the high dose
(decreased body weights, body weight gains, and food consumption,
prolonged gestation with mortality, and increased number of dead
fetuses), while offspring toxicity (including decreases in body weight,
brain weight, brain measurements and functional activities) was seen at
all doses.
    Available data indicated greater sensitivity of the developing
organism to exposure to tebuconazole, with the exception of the effects
seen in the DNT study, the degree of concern is low and there are no
residual uncertainties because the toxic endpoints in the pre- and
post-natal developmental toxicity studies were well characterized with
clear NOAELs established and the endpoint used for all risk assessments
is protective of the effects seen in these studies.
    There is concern with regard to the DNT study because of the
failure to achieve a NOAEL in that study. This concern is addressed by
a retention of FQPA SF in the form of UFL of 3X. Reduction
of the FQPA safety factor from 10 to 3X is based on a Benchmark Dose
(BMD) analysis of the datasets relevant to the adverse offspring
effects (decreased body weight and brain weight) seen at the LOAEL in
the DNT study. All of the BMDLs (the lower limit of a one-sided 95%
confidence interval on the BMD) modeled successfully on statistically
significant effects are 1-2X lower than the LOAEL. The results indicate
that an extrapolated NOAEL is not likely to be 10X lower than the LOAEL
and that use of a FQPA safety factor of 3X would not underestimate
risk. Using a 3X FQPA safety factor in the risk assessment (8.8 mg/kg/
day / 3x = 2.9 mg/kg/day) is further supported by other studies in the
tebuconazole toxicity database (with the lowest NOAELs being 3 and 2.9
mg/kg/day, from a developmental toxicity study in mice and a chronic
toxicity study in dogs, respectively [respective LOAELs 10 and 4.5 mg/
kg/day]).
    3. Conclusion. The Agency has determined that reliable data show
that it would be safe for infants and children to reduce the FQPA SF to
3x for all potential exposure scenarios. That decision is based on the
following findings:
    i. The toxicity database for tebuconazole is complete and includes
an acceptable rat developmental neurotoxicity study.
    ii. Although there is qualitative evidence of increased
susceptibility in the prenatal developmental studies in rats, mice, and
rabbits, and in the 2-generation reproduction study in rats, EPA did
not identify any residual uncertainties or concerns with regard to
these studies after establishing toxicity endpoints and traditional UFs
to be used in the risk assessment of tebuconazole.
    iii. A concern was identified with regard to the failure to
identify a NOAEL for the development effects found in the DNT study. A
FQPA safety factor of 3X was found sufficient to protect infants and
children based on the BMD analysis summarized in Unit III.D.2.
    iv. There are no residual uncertainties identified in the exposure
databases. Although the acute and chronic food exposure assessments are
refined, EPA believes that the assessments are based on reliable data
and will not underestimate exposure/risk. The drinking water estimates
were derived from conservative screening models. The residential
exposure assessment utilizes reasonable high-end variables set out in
EPA's Occupational/Residential Exposure SOPs (Standard Operating
Procedures). The aggregate assessment is based upon reasonable worst-
case residential assumptions, and

is also not likely to underestimate exposure/risk to any subpopulation,
including those comprised of infants and children.

E. Aggregate Risks and Determination of Safety

    EPA determines whether acute and chronic pesticide exposures are
safe by comparing aggregate exposure estimates to the aPAD and cPAD.
The aPAD and cPAD represent the highest safe exposures, taking into
account all appropriate SFs. EPA calculates the aPAD and cPAD by
dividing the POD by all applicable UFs. For linear cancer risks, EPA
calculates the probability of additional cancer cases given the
estimated aggregate exposure. Short-, intermediate-, and chronic-term
risks are evaluated by comparing the estimated aggregate food, water,
and residential exposure to the POD to ensure that the MOE called for
by the product of all applicable UFs is not exceeded.
    1. Acute risk. Using the exposure assumptions discussed in this
unit for acute exposure, the acute dietary exposure from food and water
to tebuconazole will occupy 53% of the aPAD for the population group
(all infants less than 1 year old) receiving the greatest exposure.
    2. Chronic risk. Using the exposure assumptions described in this
unit for chronic exposure, EPA has concluded that exposure to
tebuconazole from food and water will utilize 4% of the cPAD for the
U.S. population and 11% of the cPAD for the most highly exposed
population group (infants less than 1 year old).
    3. Short-term risk. Short-term aggregate exposure takes into
account short-term residential exposure plus chronic exposure to food
and water (considered to be a background exposure level). Tebuconazole
is currently registered for uses that could result in short-term
residential exposure and the Agency has determined that it is
appropriate to aggregate chronic exposure through food and water with
short-term residential exposures to tebuconazole.
    Using the exposure assumptions described in this unit for short-
term exposures, EPA has concluded that the short-term aggregate MOE
from dietary exposure (food + drinking water) and non-occupational/
residential handler exposure for adults using a hose-end sprayer on
ornamentals is 400. The short-term aggregate MOE from dietary exposure
and exposure from golfing is 1,800. The short-term aggregate MOE to
children from dietary exposure and exposure from wood surfaces treated
at the above ground use rate is 530. The short-term aggregate MOE to
children from dietary exposure and exposure to wood surfaces treated at
the below ground use rate is 230. The combined and aggregate MOEs for
wood treated for below ground uses exceed the Agency's LOC of 300, and
indicate a potential risk of concern. However, the MOE of 230 is based
on the assumption that 100% of a child's exposure is to below ground
wood. In reality, the probability and frequency of children contacting
wood intended for below ground use is reasonably assumed to be small
and incidental compared to wood intended for above ground uses. Treated
wood intended for below ground use is the 4 inch X 4 inch support beams
for decks and playsets, while treated wood intended for above ground
use is the decking and connecting wood. Therefore, the majority of
contact is reasonably assumed to be to wood intended for above ground
uses. The combined/aggregate MOEs for wood treated for above ground
uses does not exceed the LOC, and exposure to above ground wood is
expected to more closely represent actual exposures to children.
Therefore, the Agency considers this assessment to be a conservative
screening level assessment.
    4. Intermediate-term risk. Intermediate-term aggregate exposure
takes into account intermediate-term residential exposure plus chronic
exposure to food and water (considered to be a background exposure
level). Tebuconazole is currently registered for uses that could result
in intermediate-term residential exposure and the Agency has determined
that it is appropriate to aggregate chronic exposure through food and
water with intermediate-term residential exposures to tebuconazole.
    Since the POD, relevant exposure scenarios and exposure assumptions
used for intermediate-term aggregate risk assessments are the same as
those used for short-term aggregate risk assessments, the short-term
aggregate risk assessments represent and are protective of both short-
and intermediate-term exposure durations.
    5. Aggregate cancer risk for U.S. population. Tebuconazole is
classified as a Group C Carcinogen-Possible Human Carcinogen based on
statistically significant increase in the incidence of hepatocellular
adenoma, carcinoma, and combined adenoma/carcinomas in both sexes of
NMRI mice. The Agency believes that the chronic RfD is protective of
the cancer effects because the increased incidences of hepatocellular
adenoma, carcinomas, and combined adenoma/carcinoma were seen only at
the highest dose 1,500 ppm (279 mg/kg/day for males and 365.5 mg/kg/day
for females) in the mouse carcinogenicity study. The dose was
considered excessive. There was no evidence of carcinogenicity in rats,
and no evidence of genotoxicity for tebuconazole. The chronic RfD value
is 0.029 mg/kg/day which is approximately 9,600 fold lower than the
dose that would induce liver tumors (279 mg/kg/day).
    6. Determination of safety. Based on these risk assessments, EPA
concludes that there is a reasonable certainty that no harm will result
to the general population or to infants and children from aggregate
exposure to tebuconazole residues.

IV. Other Considerations

A. Analytical Enforcement Methodology

    Adequate GC/NPD and LC/MS/MS methods are available for both
collecting and enforcing tolerances for tebuconazole and its
metabolites in plant commodities, livestock matrices and processing
studies. The methods have been adequately validated by an independent
laboratory in conjunction with a previous petition. The method may be
requested from: Chief, Analytical Chemistry Branch, Environmental
Science Center, 701 Mapes Rd., Ft. Meade, MD 20755-5350; telephone
number:<PHONE_NUMBER>; e-mail address<EMAIL_ADDRESS>
B. International Residue Limits

    There are currently Codex, Canadian and Mexican maximum residue
limits (MRLs) for residues of tebuconazole in/on a variety of plant and
livestock commodities. The tolerance definition for residues in plants
is tebuconazole, per se, for Codex, Canada, and Mexico. For livestock
commodities, the tolerance expression is for the combined residues of
tebuconazole and HWG 2061 in the U.S. and Canada, and tebuconazole, per
se, for Codex. Where possible, the proposed tolerances levels have been
harmonized with the MRLs from Canada, Mexico, and Codex

C. Response to Comments

     The Agency received a comment from a citizen of New Jersey. The
commenter questioned the necessity of using taxpayer money through the
agency of the Interregional Research Project No. 4 to develop
pesticides, challenged the appropriateness of conducting some of the
tebuconazole field trials outside of the United States, expressed
concern over whether specific warnings were given to residents of New
Jersey prior to conducting field trials in that State, and

worried that students at Rutgers University may have been injured in
the tebuconazole toxicological tests on animals that were performed at
that facility.
    In response, EPA notes that although IR-4 has petitioned for other
tebuconazole tolerances it was not a petitioner as to the tolerances
being established today. The notice cited by the commenter contained
petitions from both IR-4 and a pesticide manufacturer. EPA is only
acting today on the petition from the pesticide manufacturer. IR-4 was
established by the U.S. Department of Agriculture to help minor
acreage, specialty crop producers obtain EPA tolerances and new
registered uses of pesticides. As to the commenter's concern with field
trials that were conducted in countries other than the United States,
the field trials that are referenced do not involve the tolerances
being acted on in this rulemaking. EPA notes, however, that frequently
field trials are conducted in other countries as well as in the United
States so that EPA can understand the range of pesticide residues that
may be present on a food. Similarly, the field trial conducted in New
Jersey was for a tolerance that is not involved in today's action.
EPA's regulations governing use of pesticides under experimental use
permits can be found at 40 CFR part 172. EPA also has regulations
governing the toxicological data testing laboratories that are designed
to insure data quality (40 CFR part 160). Federal jurisdiction
concerning the safety of workers in testing laboratories would be under
the Occupational Safety and Health Administration in the U.S.
Department of Labor. EPA has responded to similar comments from this
commenter on previous occasions. Refer to 70 FR 37686 (June 30, 2005),
70 FR 1354 (January 7, 2005), and 69 FR 63083 (October 29, 2004).

D. Revisions to Petitioned-For Tolerances

     Based upon review of the data supporting the petition, EPA
determined that the proposed tolerances should be revised as follows:
Almond, hulls increased from 5.0 ppm to 6.0 ppm; barley, hay increased
from 6.0 ppm to 7.0 ppm; barley, straw increased from 1.4 ppm to 3.5
ppm; wheat, hay increased from 6.0 to 7.0 ppm; and wheat, straw
increased from 1.4 ppm to 1.5 ppm. EPA revised these tolerance levels
based on analysis of the residue field trial data using the Agency's
Tolerance Spreadsheet in accordance with the Agency's Guidance for
Setting Pesticide Tolerances Based on Field Trial Data Standard
Operating Procedure (SOP). Additionally, tolerances were not proposed,
but are required for barley, grain at 0.15 ppm based on detectable
residues using the Agency's Tolerance Spreadsheet and wheat, grain at
0.05 ppm, because tolerances are needed even with residues are non-
detectable. Also, a separate tolerance is not needed for pistachios, as
they are considered under the nut, tree, group 14.

V. Conclusion

    Therefore, tolerances are established for residues of the fungicide
tebuconazole, alpha-[2-(4-Chlorophenyl)ethyl]-alpha-(1,1-
dimethylethyl)-1H-1,2,4-triazole-1-ethanol, in or on food commodities
nut, tree, group 14 at 0.05 ppm; almond, hulls at 6.0 ppm; barley,
grain at 0.15 ppm; barley, hay at 7.0 ppm; barley, straw at 3.5 ppm;
wheat, forage at 3.0 ppm; wheat, grain at 0.05 ppm; wheat, hay at 7.0
ppm; and wheat, straw at 1.5 ppm.

VI. Statutory and Executive Order Reviews

    This final rule establishes tolerances under section 408(d) of
FFDCA in response to a petition submitted to the Agency. The Office of
Management and Budget (OMB) has exempted these types of actions from
review under Executive Order 12866, entitled Regulatory Planning and
Review (58 FR 51735, October 4, 1993). Because this final rule has been
exempted from review under Executive Order 12866, this final rule is
not subject to Executive Order 13211, Actions Concerning Regulations
That Significantly Affect Energy Supply, Distribution, or Use (66 FR
28355, May 22, 2001) or Executive Order 13045, entitled Protection of
Children from Environmental Health Risks and Safety Risks (62 FR 19885,
April 23, 1997). This final rule does not contain any information
collections subject to OMB approval under the Paperwork Reduction Act
(PRA), 44 U.S.C. 3501 et seq., nor does it require any special
considerations under Executive Order 12898, entitled Federal Actions to
Address Environmental Justice in Minority Populations and Low-Income
Populations (59 FR 7629, February 16, 1994).
    Since tolerances and exemptions that are established on the basis
of a petition under section 408(d) of FFDCA, such as the tolerance in
this final rule, do not require the issuance of a proposed rule, the
requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et
seq.) do not apply.
    This final rule directly regulates growers, food processors, food
handlers, and food retailers, not States or tribes, nor does this
action alter the relationships or distribution of power and
responsibilities established by Congress in the preemption provisions
of section 408(n)(4) of FFDCA. As such, the Agency has determined that
this action will not have a substantial direct effect on States or
tribal governments, on the relationship between the national government
and the States or tribal governments, or on the distribution of power
and responsibilities among the various levels of government or between
the Federal Government and Indian tribes. Thus, the Agency has
determined that Executive Order 13132, entitled Federalism (64 FR
43255, August 10, 1999) and Executive Order 13175, entitled
Consultation and Coordination with Indian Tribal Governments (65 FR
67249, November 9, 2000) do not apply to this final rule. In addition,
this final rule does not impose any enforceable duty or contain any
unfunded mandate as described under Title II of the Unfunded Mandates
Reform Act of 1995 (UMRA) (Public Law 104-4).
    This action does not involve any technical standards that would
require Agency consideration of voluntary consensus standards pursuant
to section 12(d) of the National Technology Transfer and Advancement
Act of 1995 (NTTAA), Public Law 104-113, section 12(d) (15 U.S.C. 272
note).

VII. Congressional Review Act

    The Congressional Review Act, 5 U.S.C. 801 et seq., generally
provides that before a rule may take effect, the agency promulgating
the rule must submit a rule report to each House of the Congress and to
the Comptroller General of the United States. EPA will submit a report
containing this rule and other required information to the U.S. Senate,
the U.S. House of Representatives, and the Comptroller General of the
United States prior to publication of this final rule in the Federal
Register. This final rule is not a ``major rule'' as defined by 5
U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

    Environmental protection, Administrative practice and procedure,
Agricultural commodities, Pesticides and pests, Reporting and
recordkeeping requirements.

    Dated: May 2, 2008.
Lois Rossi,
Director, Registration Division, Office of Pesticide Programs.

0
Therefore, 40 CFR chapter I is amended as follows:

PART 180--[AMENDED]

0
1. The authority citation for part 180 continues to read as follows:

    Authority: 21 U.S.C. 321(q), 346a and 371.

0
2. Section 180.474 is amended in paragraph (a)(1) in the table by
alphabetically adding the commodities Almond, hulls and Nut, tree,
group 14 and by revising the following commodities to read as follows:

Sec.  180.474  Tebuconazole; tolerances for residues.

    (a) * * *

------------------------------------------------------------------------
                      Commodity                        Parts per million
------------------------------------------------------------------------
Almond, hulls........................................                6.0
                                * * * * *
Barley, grain........................................               0.15
Barley, hay..........................................                7.0
Barley, straw........................................                3.5
                                * * * * *
Nut, tree, group 14..................................               0.05
                                * * * * *
Wheat, forage........................................                3.0
Wheat, grain.........................................               0.05
Wheat, hay...........................................                7.0
Wheat, straw.........................................                1.5
------------------------------------------------------------------------

* * * * *

[FR Doc. E8-10506 Filed 5-13-08; 8:45 am]

BILLING CODE 6560-50-S


[Federal Register Volume 87, Number 92 (Thursday, May 12, 2022)]
[Notices]
[Pages 29161-29162]
[FR Doc No: 2022-10131]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-1875]

Financial Transparency and Efficiency of the Prescription Drug
User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee
Amendments; Public Meeting; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing the following public meeting entitled ``Financial
Transparency and Efficiency of the Prescription Drug User Fee Act,
Biosimilar User Fee Act, and Generic Drug User Fee Amendments.'' The
topic to be discussed is the financial transparency and efficiency of
the Prescription Drug User Fee Act, Biosimilar User Fee Act, and
Generic Drug User Fee Amendments.

DATES: The public meeting will be held on June 7, 2022, from 9:30 a.m.
to 10:50 a.m. via ZoomGov. Submit either electronic or written comments
on this public meeting by July 7, 2022. See the SUPPLEMENTARY
INFORMATION section for registration date and information.

ADDRESSES: The public meeting will be held virtually due to extenuating
circumstances.
    You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. Electronic comments must be
submitted on or before July 7, 2022. The https://www.regulations.gov
electronic filing system will accept comments until 11:59 p.m. Eastern
Time at the end of July 7, 2022. Comments received by mail/hand
delivery/courier (for written/paper submissions) will be considered
timely if they are postmarked or the delivery service acceptance
receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2019-N-1875 for ``Financial Transparency and Efficiency of the
Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic
Drug User Fee Amendments; Public Meeting; Request for Comments.''
Received comments, those filed in a timely manner (see ADDRESSES), will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Monica Ellerbe, Office of Finance,
Budget, Acquisition, and Planning, 4041 Powder Mill Rd., Rm. 72044,
Beltsville, MD 20750,<PHONE_NUMBER>, [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    The meeting will include presentations from FDA on topics related
to the financial management of certain user fee programs, including
presentations on the following: (1) The 5-year financial plan for the
Prescription Drug User Fee Act (PDUFA) VI, Biosimilar User Fee Act
(BsUFA) II, and Generic Drug User Fee Amendments (GDUFA) II and (2) the
Agency's

progress in implementing resource capacity planning and modernized time
reporting. This meeting is intended to satisfy FDA's commitment to host
an annual public meeting in the third quarter of each fiscal year
beginning in FY 2019 and can be found in the Commitment Letters listed
below (sections II.B.3 of PDUFA VI (p. 38), IV.B.3 of BsUFA II (p. 29),
and VI.B.4 of GDUFA II (p.22)).
    This public meeting is intended to meet performance commitments
included in the respective Commitment Letters for PDUFA VI, BsUFA II,
and GDUFA II. These user fee programs were reauthorized as part of the
FDA Reauthorization Act of 2017 signed by the President on August 18,
2017. The complete set of performance goals for each program are
available at:

 PDUFA VI program: https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM511438.pdf
 BsUFA II program: https://www.fda.gov/downloads/forindustry/userfees/biosimilaruserfeeactbsufa/ucm521121.pdf
 GDUFA II program: https://www.fda.gov/downloads/forindustry/userfees/genericdruguserfees/ucm525234.pdf

    Each of these user fee programs' Commitment Letters included a set
of commitments related to financial management. These included
commitments to publish a 5-year financial plan and update that plan
annually, develop resource capacity planning capability and modernize
time reporting practices, and have a third-party evaluation of resource
management practices for these user fee programs. In addition, each
user fee program includes a commitment to host a public meeting in the
third quarter of each fiscal year, beginning in FY 2019, to discuss
specific topics.

II. Topics for Discussion at the Public Meeting

    This meeting will provide FDA the opportunity to update interested
public stakeholders on topics related to the financial management of
PDUFA VI, BsUFA II, and GDUFA II. These topics include the 5-year
financial plans for each of these programs and FDA's progress towards
implementing resource capacity planning and modernizing its time
reporting approach.

III. Participating in the Public Meeting

    Registration: To register for the public meeting, please visit the
following website: https://fda.zoomgov.com/webinar/register/WN_C5cXHj38R6WeNg1ZuqbKaA. Please provide complete contact information
for each attendee, including name, title, affiliation, address, email,
and telephone.
    Persons interested in attending this public meeting must register
by June 2, 2022, at 11:59 p.m. Eastern Time. We will let registrants
know if registration closes before the day of the public meeting.
    If you need special accommodations due to a disability, please
contact Monica Ellerbe at [email protected] by June 2, 2022,
at 11:59 p.m. Eastern Time.
    Streaming Webcast of the Public Meeting: This public meeting will
be a webcast. To register for the public meeting and obtain the webcast
information, please visit the following website: https://fda.zoomgov.com/webinar/register/WN_C5cXHj38R6WeNg1ZuqbKaA.
    Transcripts: Please be advised that as soon as a transcript of the
public meeting is available, it will be accessible at https://www.regulations.gov. It may be viewed at the Dockets Management Staff
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.

    Dated: May 6, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-10131 Filed 5-11-22; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 87, Number 127 (Tuesday, July 5, 2022)]
[Rules and Regulations]
[Pages 39745-39746]
[FR Doc No: 2022-14199]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2021-0971; Airspace Docket No. 21-AGL-8]
RIN 2120-AA66

Amendment of VOR Federal Airway V-44 and Revocation of VOR
Federal Airway V-446 in the Vicinity of Samsville, IL

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This action amends VHF Omnidirectional Range (VOR) Federal
airway V-44 and revokes VOR Federal airway V-446. The FAA is taking
this action due to the planned decommissioning of the VOR portion of
the Samsville, IL, VOR/Distance Measuring Equipment (VOR/DME)
navigational aid (NAVAID). The Samsville VOR is being decommissioned in
support of the FAA's VOR Minimum Operational Network (MON) program.

DATES: Effective date 0901 UTC, September 8, 2022. The Director of the
Federal Register approves this incorporation by reference action under
1 CFR part 51, subject to the annual revision of FAA Order JO 7400.11
and publication of conforming amendments.

ADDRESSES: FAA Order JO 7400.11F, Airspace Designations and Reporting
Points, and subsequent amendments can be viewed online at https://www.faa.gov/air_traffic/publications/. For further information, you can
contact the Rules and Regulations Group, Federal Aviation
Administration, 800 Independence Avenue SW, Washington, DC 20591;
telephone:<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Colby Abbott, Rules and Regulations
Group, Office of Policy, Federal Aviation Administration, 800
Independence Avenue SW, Washington, DC 20591; telephone: (202) 267-
8783.

SUPPLEMENTARY INFORMATION:

Authority for This Rulemaking

    The FAA's authority to issue rules regarding aviation safety is
found in Title 49 of the United States Code. Subtitle I, Section 106
describes the authority of the FAA Administrator. Subtitle VII,
Aviation Programs, describes in more detail the scope of the agency's
authority. This rulemaking is promulgated under the authority described
in Subtitle VII, Part A, Subpart I, Section 40103. Under that section,
the FAA is charged with prescribing regulations to assign the use of
the airspace necessary to ensure the safety of aircraft and the
efficient use of airspace. This regulation is within the scope of that
authority as it modifies the route structure as necessary to preserve
the safe and efficient flow of air traffic within the National Airspace
System.

History

    The FAA published a notice of proposed rulemaking for Docket No.
FAA-2021-0971 in the Federal Register (86 FR 62962; November 15, 2021),
amending VOR Federal airway V-44 and revoking VOR Federal airway V-446
in the vicinity of Samsville, IL. The proposed actions were due to the
planned decommissioning of the VOR portion of the Samsville, IL, VOR/
DME NAVAID. Interested parties were invited to participate in this
rulemaking effort by submitting written comments on the proposal. No
comments were received.
    VOR Federal airways are published in paragraph 6010(a) of FAA Order
JO 7400.11F, dated August 10, 2021, and effective September 15, 2021,
which is incorporated by reference in 14 CFR 71.1. The ATS routes
listed in this document will be published subsequently in FAA Order JO
7400.11.

Availability and Summary of Documents for Incorporation by Reference

    This document amends FAA Order JO 7400.11F, Airspace Designations
and Reporting Points, dated August 10, 2021, and effective September
15, 2021. FAA Order JO 7400.11F is publicly available as listed in the
ADDRESSES section of this document. FAA Order JO 7400.11F lists Class
A, B, C, D, and E airspace areas, air traffic service routes, and
reporting points.

The Rule

    The FAA is amending 14 CFR part 71 to amend VOR Federal airway V-44
and remove VOR Federal airway V-446 due to the planned decommissioning
of the Samsville, IL, VOR. The VOR Federal airway actions are described
below.
    V-44: V-44 extends between the Columbia, MO, VOR/DME and the
Samsville, IL, VOR/DME; and between the Falmouth, KY, VOR/DME and the
Albany, NY, VOR/Tactical Air Navigation (VORTAC). The airspace within
restricted areas R-4001B, R-5002A, R-5002B, and R-5002E are excluded
when active; the airspace within V-139 and V-308 airways are excluded;
and the airspace below 2,000 feet mean sea level (MSL) outside the
United States is excluded. The airway segment between the Centralia,
IL,

VORTAC and the Samsville, IL, VOR/DME is removed. Additionally, the
exclusions regarding the airspace within R-4001B, R-5002A, R-5002B, and
R-5002E when active, and the airspace within the V-139 and V-308
airways are removed as well. The unaffected portions of the existing
airway remain as charted.
    V-446: V-446 extends between the Troy, IL, VORTAC and the
Samsville, IL, VOR/DME. The airway is removed in its entirety.
    All NAVAID radials listed in the VOR Federal airway description
below are unchanged and stated in True degrees.
    FAA Order JO 7400.11, Airspace Designations and Reporting Points,
is published yearly and effective on September 15.

Regulatory Notices and Analyses

    The FAA has determined that this regulation only involves an
established body of technical regulations for which frequent and
routine amendments are necessary to keep them operationally current.
It, therefore: (1) is not a ``significant regulatory action'' under
Executive Order 12866; (2) is not a ``significant rule'' under
Department of Transportation (DOT) Regulatory Policies and Procedures
(44 FR 11034; February 26, 1979); and (3) does not warrant preparation
of a regulatory evaluation as the anticipated impact is so minimal.
Since this is a routine matter that will only affect air traffic
procedures and air navigation, it is certified that this rule, when
promulgated, will not have a significant economic impact on a
substantial number of small entities under the criteria of the
Regulatory Flexibility Act.

Environmental Review

    The FAA has determined that this action of amending VOR Federal
airway V-44 and revoking VOR Federal airway V-446, due to the planned
decommissioning of the VOR portion of the Samsville, IL, VOR/DME
NAVAID, qualifies for categorical exclusion under the National
Environmental Policy Act (42 U.S.C. 4321 et seq.) and its implementing
regulations at 40 CFR part 1500, and in accordance with FAA Order
1050.1F, Environmental Impacts: Policies and Procedures, paragraph 5-
6.5a, which categorically excludes from further environmental impact
review rulemaking actions that designate or modify classes of airspace
areas, airways, routes, and reporting points (see 14 CFR part 71,
Designation of Class A, B, C, D, and E Airspace Areas; Air Traffic
Service Routes; and Reporting Points). As such, this action is not
expected to result in any potentially significant environmental
impacts. In accordance with FAA Order 1050.1F, paragraph 5-2 regarding
Extraordinary Circumstances, the FAA has reviewed this action for
factors and circumstances in which a normally categorically excluded
action may have a significant environmental impact requiring further
analysis. The FAA has determined that no extraordinary circumstances
exist that warrant preparation of an environmental assessment or
environmental impact study.

List of Subjects in 14 CFR Part 71

    Airspace, Incorporation by reference, Navigation (air).

The Amendment

    In consideration of the foregoing, the Federal Aviation
Administration amends 14 CFR part 71 as follows:

PART 71--DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR
TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

0
1. The authority citation for 14 CFR part 71 continues to read as
follows:

    Authority:  49 U.S.C. 106(f), 106(g); 40103, 40113, 40120; E.O.
10854, 24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

Sec.  71.1   [Amended]

0
2. The incorporation by reference in 14 CFR 71.1 of FAA Order JO
7400.11F, Airspace Designations and Reporting Points, dated August 10,
2021, and effective September 15, 2021, is amended as follows:

Paragraph 6010(a) Domestic VOR Federal Airways.

* * * * *

V-44 [Amended]

    From Columbia, MO; INT Columbia 131[deg] and Foristell, MO,
262[deg] radials; Foristell; to Centralia, IL. From Falmouth, KY;
York, KY; Parkersburg, WV; Morgantown, WV; Martinsburg, WV; INT
Martinsburg 094[deg] and Baltimore, MD, 300[deg] radials; Baltimore;
INT Baltimore 122[deg] and Sea Isle, NJ, 267[deg] radials; Sea Isle;
INT Sea Isle 040[deg] and Deer Park, NY, 209[deg] radials; Deer
Park; INT Deer Park 041[deg] and Bridgeport, CT, 133[deg] radials;
Bridgeport; INT Bridgeport 324[deg] and Pawling, NY, 160[deg]
radials; Pawling; INT Pawling 342[deg] and Albany, NY, 181[deg]
radials; to Albany. The airspace below 2,000 feet MSL outside the
United States is excluded.
* * * * *

V-446 [Removed]

* * * * *

    Issued in Washington, DC, on June 23, 2022.
Scott M. Rosenbloom,
Manager, Airspace Rules and Regulations.
[FR Doc. 2022-14199 Filed 7-1-22; 8:45 am]
BILLING CODE 4910-13-P


Kathy Kaufman/RTP/USEPA/US

04/28/2008 10:36 AM

To

Tricia Crabtree/RTP/USEPA/US@EPA

cc

Subject

next set of emails for Pb RIA docket

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

----- Forwarded by Kathy Kaufman/RTP/USEPA/US on 04/28/2008 10:34 AM -----

"King, Heidi R."<EMAIL_ADDRESS> 04/23/2008 08:00 PM

To

Kathy Kaufman/RTP/USEPA/US@EPA

cc

Subject

RE: Responses to interagency questions on the Pb RIA

Thank you !

-----Original Message-----

From<EMAIL_ADDRESS> <EMAIL_ADDRESS> Sent: Wednesday, April 23, 2008 10:46 AM

To: King, Heidi R.

Cc<EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> Subject: Re: Responses to interagency questions on the Pb RIA

Heidi, quick typo correction in the file I sent yesterday (see attached

email):

In the answer to the first question, "from leaded avgas" was left out of

the following sentence.  It should read:

"In addition, we do not have cost estimates regarding the control of

lead emissions from leaded avgasand we can't assume a priori that these

control measures would be either more, or less expensive than point

source controls."

Thanks.  Sorry about that.

-- Kathy

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

             Kathy

             Kaufman/RTP/USEP

             A/US                                                    To

                                      "King, Heidi R."

             04/22/2008 03:02<EMAIL_ADDRESS>

             PM                                                      cc

                                      Charlotte

                                      Bertrand/DC/USEPA/US@EPA,

                                      Nathalie Simon/DC/USEPA/US@EPA,

                                      Ron Evans/RTP/USEPA/US@EPA, Lydia

                                      Wegman/RTP/USEPA/US@EPA, Tricia

                                      Crabtree/RTP/USEPA/US@EPA, Neal

                                      Fann/RTP/USEPA/US@EPA

                                                                Subject

                                      Responses to interagency

                                      questions on the Pb RIA(Document

                                      link: Kathy Kaufman)

Heidi -- we drafted responses to the questions you had forwarded.

Please see the attached.

Thanks.

-- Kathy

(See attached file: Interagency responses 4-22-08.doc)

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

----- Forwarded by Kathy Kaufman/RTP/USEPA/US on 04/28/2008 10:34 AM -----

"King, Heidi R."<EMAIL_ADDRESS> 04/24/2008 10:25 AM

To

Ron Evans/RTP/USEPA/US@EPA, Lydia Wegman/RTP/USEPA/US@EPA, Margaret Morrison/RTP/USEPA/US@EPA, Kathy Kaufman/RTP/USEPA/US@EPA

cc

Subject

Ron/Kathy: RIA conversation at 10am Friday?

Ron and Kathy,

Would it be possible to set aside some time at 10am on Friday to continue dialogue on the Pb NAAQS RIA?  I have a few more interagency comments, I’ll send something in advance, but it will also be helpful to preserve time for discussion.  As always, I appreciate your time.

Best regards,

heidi

----- Forwarded by Kathy Kaufman/RTP/USEPA/US on 04/28/2008 10:34 AM -----

"King, Heidi R."<EMAIL_ADDRESS> 04/24/2008 12:28 PM

To

Margaret Morrison/RTP/USEPA/US@EPA, Ron Evans/RTP/USEPA/US@EPA

cc

Kathy Kaufman/RTP/USEPA/US@EPA, Lydia Wegman/RTP/USEPA/US@EPA

Subject

RE: Ron/Kathy: RIA conversation at 10am Friday?

perfect

-----Original Message-----

From<EMAIL_ADDRESS> <EMAIL_ADDRESS> Sent: Thursday, April 24, 2008 12:17 PM

To<EMAIL_ADDRESS> Cc: King, Heidi R<EMAIL_ADDRESS> <EMAIL_ADDRESS> Subject: RE: Ron/Kathy: RIA conversation at 10am Friday?

Ok.  Heidi, we will go with 11:30am & use x4407 as the call-in #.

Thanks, everyone.

Margaret Morrison (MC C504-02)

US EPA/OAQPS/HEID/IO

Telephone:<PHONE_NUMBER>

Fax:<PHONE_NUMBER>

<EMAIL_ADDRESS>

             Ron

             Evans/RTP/USEPA/

             US                                                      To

                                      Margaret

             04/24/2008 12:10         Morrison/RTP/USEPA/US@EPA

             PM                                                      cc

                                      "King, Heidi R."

<EMAIL_ADDRESS>

                                      Kathy Kaufman/RTP/USEPA/US@EPA,

                                      Lydia Wegman/RTP/USEPA/US@EPA

                                                                Subject

                                      RE: Ron/Kathy: RIA conversation

                                      at 10am Friday?(Document link:

                                      Margaret Morrison)

I would prefer 11:30, I don't have to move another meeting to make that

slot.

             Margaret

             Morrison/RTP/USE

             PA/US                                                   To

                                      "King, Heidi R."

             04/24/2008 12:07<EMAIL_ADDRESS>

             PM                                                      cc

                                      Kathy Kaufman/RTP/USEPA/US@EPA,

                                      Lydia Wegman/RTP/USEPA/US@EPA,

                                      Ron Evans/RTP/USEPA/US@EPA

                                                                Subject

                                      RE: Ron/Kathy: RIA conversation

                                      at 10am Friday?(Document link:

                                      Ron Evans - New)

I can work around 11:30am or 1:00pm.  Ron, let me know.

Margaret Morrison (MC C504-02)

US EPA/OAQPS/HEID/IO

Telephone:<PHONE_NUMBER>

Fax:<PHONE_NUMBER>

<EMAIL_ADDRESS>

             "King, Heidi R."

             <Heidi_R._King@o

             mb.eop.gov>                                             To

                                      Ron Evans/RTP/USEPA/US@EPA

             04/24/2008 11:52                                        cc

             AM                       Kathy Kaufman/RTP/USEPA/US@EPA,

                                      Lydia Wegman/RTP/USEPA/US@EPA,

                                      Margaret

                                      Morrison/RTP/USEPA/US@EPA

                                                                Subject

                                      RE: Ron/Kathy: RIA conversation

                                      at 10am Friday?

11:30?

1?

-----Original Message-----

From<EMAIL_ADDRESS><EMAIL_ADDRESS> Sent: Thursday, April 24, 2008 11:47 AM

To: King, Heidi R.

Cc<EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS> Subject: Re: Ron/Kathy: RIA conversation at 10am Friday?

Unfortunately, you hit about the only time on my calendar which has an

unmovable meeting.   I am part of the team meeting with Courtney Higgins

(of OMB for Lydia and Kathy's benefit) at 10:30 on the petroleum

refineries package.   We have been told that there will be some

questions about the benefits analysis and I need to participate in that

meeting.

Is there any other time which would work for you?   Generally I can move

other meetings if needed.   If you can give us a few options, I am sure

we can find a good time.

             "King, Heidi R."

             <Heidi_R._King@o

             mb.eop.gov>                                             To

                                      Ron Evans/RTP/USEPA/US@EPA, Lydia

             04/24/2008 10:25         Wegman/RTP/USEPA/US@EPA, Margaret

             AM                       Morrison/RTP/USEPA/US@EPA, Kathy

                                      Kaufman/RTP/USEPA/US@EPA

                                                                     cc

                                                                Subject

                                      Ron/Kathy: RIA conversation at

                                      10am Friday?

Ron and Kathy,

Would it be possible to set aside some time at 10am on Friday to

continue dialogue on the Pb NAAQS RIA?  I have a few more interagency

comments, I'll send something in advance, but it will also be helpful to

preserve time for discussion.  As always, I appreciate your time.

Best regards,

heidi

----- Forwarded by Kathy Kaufman/RTP/USEPA/US on 04/28/2008 10:34 AM -----

"King, Heidi R."<EMAIL_ADDRESS> 04/24/2008 04:27 PM

To

Kathy Kaufman/RTP/USEPA/US@EPA

cc

Charlotte Bertrand/DC/USEPA/US@EPA, Lydia Wegman/RTP/USEPA/US@EPA, Nathalie Simon/DC/USEPA/US@EPA, Neal Fann/RTP/USEPA/US@EPA, Ron Evans/RTP/USEPA/US@EPA, Tricia Crabtree/RTP/USEPA/US@EPA

Subject

RE: Responses to interagency questions on the Pb RIA

Hi Kathy,

Any word on the additional materials re: dust?

Commenters asking --

heidi

-----Original Message-----

From<EMAIL_ADDRESS> <EMAIL_ADDRESS> Sent: Wednesday, April 23, 2008 10:46 AM

To: King, Heidi R.

Cc<EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> Subject: Re: Responses to interagency questions on the Pb RIA

Heidi, quick typo correction in the file I sent yesterday (see attached

email):

In the answer to the first question, "from leaded avgas" was left out of

the following sentence.  It should read:

"In addition, we do not have cost estimates regarding the control of

lead emissions from leaded avgasand we can't assume a priori that these

control measures would be either more, or less expensive than point

source controls."

Thanks.  Sorry about that.

-- Kathy

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

             Kathy

             Kaufman/RTP/USEP

             A/US                                                    To

                                      "King, Heidi R."

             04/22/2008 03:02<EMAIL_ADDRESS>

             PM                                                      cc

                                      Charlotte

                                      Bertrand/DC/USEPA/US@EPA,

                                      Nathalie Simon/DC/USEPA/US@EPA,

                                      Ron Evans/RTP/USEPA/US@EPA, Lydia

                                      Wegman/RTP/USEPA/US@EPA, Tricia

                                      Crabtree/RTP/USEPA/US@EPA, Neal

                                      Fann/RTP/USEPA/US@EPA

                                                                Subject

                                      Responses to interagency

                                      questions on the Pb RIA(Document

                                      link: Kathy Kaufman)

Heidi -- we drafted responses to the questions you had forwarded.

Please see the attached.

Thanks.

-- Kathy

(See attached file: Interagency responses 4-22-08.doc)

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

----- Forwarded by Kathy Kaufman/RTP/USEPA/US on 04/28/2008 10:34 AM -----

"King, Heidi R."<EMAIL_ADDRESS> 04/25/2008 07:40 AM

To

Kathy Kaufman/RTP/USEPA/US@EPA

cc

Charlotte Bertrand/DC/USEPA/US@EPA, Lydia Wegman/RTP/USEPA/US@EPA, Nathalie Simon/DC/USEPA/US@EPA, Neal Fann/RTP/USEPA/US@EPA, Ron Evans/RTP/USEPA/US@EPA, Tricia Crabtree/RTP/USEPA/US@EPA

Subject

RE: Responses to interagency questions on the Pb RIA

I'm sure there will be plenty of other items to discuss, I did not

organize in interagency group but rather am assembling comments -- I'm

working on assembling comments now and hopefully will have something to

you in advance of the mtg

At the very least I'll be somewhat organized.

Thanks again, Kathy --

heidi

-----Original Message-----

From<EMAIL_ADDRESS> <EMAIL_ADDRESS> Sent: Friday, April 25, 2008 12:07 AM

To: King, Heidi R.

Cc<EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> Subject: RE: Responses to interagency questions on the Pb RIA

Heidi -- should be coming in the a.m.  Am awaiting an o.k. from one key

office.

Tom Pace, who put together the information, is not available for our

meeting tomorrow, though.  He's out tomorrow.  I'm assuming there will

be plenty else to discuss?

Thanks.

- Kathy

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

To      Kathy Kaufman/RTP/USEPA/US@EPA

      cc      Charlotte Bertrand/DC/USEPA/US@EPA, Lydia

Wegman/RTP/USEPA/US@EPA, Nathalie Simon/DC/USEPA/US@EPA, Neal

Fann/RTP/USEPA/US@EPA, Ron Evans/RTP/USEPA/US@EPA, Tricia

Crabtree/RTP/USEPA/US@EPA

      bcc

      Subject       RE: Responses to interagency questions on

the Pb RIA

"King, Heidi R."<EMAIL_ADDRESS> 04/24/2008 04:27 PM AST

Hi Kathy,

Any word on the additional materials re: dust?

Commenters asking --

heidi

-----Original Message-----

From<EMAIL_ADDRESS> <EMAIL_ADDRESS> Sent: Wednesday, April 23, 2008 10:46 AM

To: King, Heidi R.

Cc<EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> Subject: Re: Responses to interagency questions on the Pb RIA

Heidi, quick typo correction in the file I sent yesterday (see attached

email):

In the answer to the first question, "from leaded avgas" was left out of

the following sentence.  It should read:

"In addition, we do not have cost estimates regarding the control of

lead emissions from leaded avgasand we can't assume a priori that these

control measures would be either more, or less expensive than point

source controls."

Thanks.  Sorry about that.

-- Kathy

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

Kathy

Kaufman/RTP/USEP

A/US                                                    To

"King, Heidi R."

04/22/2008 03:02<EMAIL_ADDRESS> PM                                                      cc

Charlotte

Bertrand/DC/USEPA/US@EPA,

Nathalie Simon/DC/USEPA/US@EPA,

Ron Evans/RTP/USEPA/US@EPA, Lydia

Wegman/RTP/USEPA/US@EPA, Tricia

Crabtree/RTP/USEPA/US@EPA, Neal

Fann/RTP/USEPA/US@EPA

Subject

Responses to interagency

questions on the Pb RIA(Document

link: Kathy Kaufman)

Heidi -- we drafted responses to the questions you had forwarded.

Please see the attached.

Thanks.

-- Kathy

(See attached file: Interagency responses 4-22-08.doc)

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

----- Forwarded by Kathy Kaufman/RTP/USEPA/US on 04/28/2008 10:34 AM -----

"King, Heidi R."<EMAIL_ADDRESS> 04/25/2008 09:56 AM

To

Kathy Kaufman/RTP/USEPA/US@EPA, "Lee, Amanda I." <EMAIL_ADDRESS>"Beck, Nancy"<EMAIL_ADDRESS>"Schwab, Margo"<EMAIL_ADDRESS> cc

Charlotte Bertrand/DC/USEPA/US@EPA, Lydia Wegman/RTP/USEPA/US@EPA, Nathalie Simon/DC/USEPA/US@EPA, Neal Fann/RTP/USEPA/US@EPA, Ron Evans/RTP/USEPA/US@EPA, Tricia Crabtree/RTP/USEPA/US@EPA

Subject

Kathy - Items we'd like to cover at 11:30

Hello again Kathy,

I'm still reading, but here are some topics we could address in our

meeting this morning at 11:30 :

- Unidentified Controls / Extrap Costs  (This is probably the highest

priority)

- Benefits baseline

- Follow up on Amanda's question about rules assumed in the baseline

- Scenario selection - OMB recommends that .5 mg/m3 should also be

analyzed

- Briefly: Could we walk through again how we moved from 189 monitors to

36 (regrets to be asking for a repeat on this subject)

- Air Qual Assessment Tool:  Re-entrained dust component, plan to

change/update for final rule RIA

Next steps, including:

- Setting aside time to walk through a few line-by-line comments and/or

questions

- Outline what changes are likely to be feasible and high priority

before signature of this proposal

- Begin to identify changes for draft final rule RIA

I hope this is helpful!  Regrets for the short notice;

heidi

-----Original Message-----

From: King, Heidi R.

Sent: Friday, April 25, 2008 7:40 AM

To<EMAIL_ADDRESS> Cc<EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> Subject: RE: Responses to interagency questions on the Pb RIA

I'm sure there will be plenty of other items to discuss, I did not

organize in interagency group but rather am assembling comments -- I'm

working on assembling comments now and hopefully will have something to

you in advance of the mtg

At the very least I'll be somewhat organized.

Thanks again, Kathy --

heidi

-----Original Message-----

From<EMAIL_ADDRESS> <EMAIL_ADDRESS> Sent: Friday, April 25, 2008 12:07 AM

To: King, Heidi R.

Cc<EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> Subject: RE: Responses to interagency questions on the Pb RIA

Heidi -- should be coming in the a.m.  Am awaiting an o.k. from one key

office.

Tom Pace, who put together the information, is not available for our

meeting tomorrow, though.  He's out tomorrow.  I'm assuming there will

be plenty else to discuss?

Thanks.

- Kathy

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

To      Kathy Kaufman/RTP/USEPA/US@EPA

      cc      Charlotte Bertrand/DC/USEPA/US@EPA, Lydia

Wegman/RTP/USEPA/US@EPA, Nathalie Simon/DC/USEPA/US@EPA, Neal

Fann/RTP/USEPA/US@EPA, Ron Evans/RTP/USEPA/US@EPA, Tricia

Crabtree/RTP/USEPA/US@EPA

      bcc

      Subject       RE: Responses to interagency questions on

the Pb RIA

"King, Heidi R."<EMAIL_ADDRESS> 04/24/2008 04:27 PM AST

Hi Kathy,

Any word on the additional materials re: dust?

Commenters asking --

heidi

-----Original Message-----

From<EMAIL_ADDRESS> <EMAIL_ADDRESS> Sent: Wednesday, April 23, 2008 10:46 AM

To: King, Heidi R.

Cc<EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> <EMAIL_ADDRESS><EMAIL_ADDRESS> Subject: Re: Responses to interagency questions on the Pb RIA

Heidi, quick typo correction in the file I sent yesterday (see attached

email):

In the answer to the first question, "from leaded avgas" was left out of

the following sentence.  It should read:

"In addition, we do not have cost estimates regarding the control of

lead emissions from leaded avgasand we can't assume a priori that these

control measures would be either more, or less expensive than point

source controls."

Thanks.  Sorry about that.

-- Kathy

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>

Kathy

Kaufman/RTP/USEP

A/US                                                    To

"King, Heidi R."

04/22/2008 03:02<EMAIL_ADDRESS> PM                                                      cc

Charlotte

Bertrand/DC/USEPA/US@EPA,

Nathalie Simon/DC/USEPA/US@EPA,

Ron Evans/RTP/USEPA/US@EPA, Lydia

Wegman/RTP/USEPA/US@EPA, Tricia

Crabtree/RTP/USEPA/US@EPA, Neal

Fann/RTP/USEPA/US@EPA

Subject

Responses to interagency

questions on the Pb RIA(Document

link: Kathy Kaufman)

Heidi -- we drafted responses to the questions you had forwarded.

Please see the attached.

Thanks.

-- Kathy

(See attached file: Interagency responses 4-22-08.doc)

Kathy Kaufman

EPA/OAQPS Mail Code C539-03

Research Triangle Park, NC 27711

Phone<PHONE_NUMBER>

Fax<PHONE_NUMBER>